TABLE 2.

Effect of treatments on serum lipoprotein levels at baseline and at three months after the start of treatment

Parameter	Time interval	Atorvastatin* (n=25)	Atorvastatin + fenofibrate† (n=21)	Simvastatin‡ (n=23)	Simvastatin + fenofibrate§ (n=22)
Total cholesterol, mmol/L	Baseline	4.07±0.88	3.92±1.21	3.91±0.81	3.87±0.83
	Three months	3.89±1.11	4.05±0.66	3.81±1.39	3.63±0.80
Triglycerides, mmol/L	Baseline	1.59±0.84	1.71±1.23	1.52±0.86	1.50±0.87
	Three months	1.47±0.68	1.19±0.52¶	1.35±1.11	1.21±0.52
HDL-C, mmol/L	Baseline	0.98±0.24	0.91±0.24	0.91±0.22	0.91±0.22
	Three months	1.08±0.24¶	1.22±0.22¶	1.13±0.33¶	1.13±0.34¶
LDL-C, mmol/L	Baseline	2.63±0.87	2.37±0.86	2.42±0.60	2.39±0.63
	Three months	2.14±0.89¶	2.25±0.48	1.99±0.68¶	1.99±0.68¶
VLDL-C, mmol/L	Baseline	0.75±0.40	0.81±0.58	0.71±0.41	0.72±0.41
	Three months	0.69±0.39	0.56±0.25¶	0.63±0.52	0.63±0.52
LDL-C/HDL-C	Baseline	2.87±1.35	2.66±0.82	2.89±1.05	3.13±1.92
	Three months	2.06±0.95¶	1.91±0.50¶	1.92±0.81¶	1.92±0.79¶
Total cholesterol/HDL-C	Baseline	4.33±1.25	4.41±1.42	4.42±1.29	4.37±1.31
	Three months	3.71±1.2¶	3.42±0.69	3.66±1.77¶	3.66±1.78¶

^*Data are expressed as mean ± SD. Degrees of freedom =24,

^†20,

^‡22,

^§21;

^¶Significant change from baseline values, Student’s t test, P<0.05. HDL-C High-density lipoprotein cholesterol; LDL-C Low-density lipoprotein cholesterol; VLDL-C Very low-density lipoprotein cholesterol